Portable Lab-on-a-chip Flow Cytometer: Prototype and Application Development

描述（申请人提供）：便携式芯片流式细胞仪：原型与应用开发纳米分选研究及相关其他项目信息这里提出的片上实验室纳米排序设备推进了第一阶段测试原型项目的成果。该设备将通过改善获取和降低分选流式细胞术的成本和复杂性来获得商业成功。此外，它将扩大该设备的应用范围，包括用于诊断、预后和个性化医疗的转化和临床护理点流式细胞术应用。在完成了第一阶段项目的关键里程碑后，例如可批量生产的注塑芯片、先进的信号检测和处理以及关键性能指标，我们建议扩展能力，以与同类最佳设备竞争。我们这个项目的目标是创建一个设备（NanoSort-1或NS-1），它将改进使用单个光电倍增管（PMT）进行6色检测的性能参数，使用低剪切应力压电（PZT）执行器进行4路分选，以及一个鲁棒的数字信号处理算法(颜色-时空（成本）实现，允许每秒10,000个事件的检测和分选。除了这些创新之外，我们将使用当前的良好生产工艺（cGMP）构建设备，以确保该设备将通过UL和CE认证，并可扩展到每年10,000台。我们将与加州大学圣地亚哥分校的研究人员和设备制造商（Becton-Dickinson和Life Technologies）进行协商，验证该设备。

DESCRIPTION (provided by applicant): Portable Lab-on-a-chip Flow Cytometer: Prototype and Application Development NanoSort RESEARCH & RELATED Other Project Information 7. PROJECT SUMMARY The lab-on-a-chip NanoSort device proposed here advances the achievements of the Phase I Beta Prototype project. This device will be appropriate for commercial success by improving access to and reducing the cost and complexity of sorting flow cytometry. Furthermore, it will expand the applications that this device can serve, including translational and clinical point-of-care flow cytometry applications for diagnostics, prognosis, and personalized medicine. Having completed key milestones in the Phase I program, such as mas- producible injection molded chips, advanced signal detection and processing and key performance metrics, we propose to extend the capabilities to compete with best-in-class devices. Our Aims for this project are to create a device (NanoSort-1 or NS-1) that will have improved performance parameters of 6-color detection with a single photomultiplier tube (PMT), 4-way sorting using low shear stress piezoelectric (PZT) actuators, and a robust digital signal processing algorithm (Color-Space-Time (CoST) implementation that allows 10,000 events per second detection and sorting. In addition to these innovations, we will construct the device using current good manufacturing processes (cGMP) to assure that this device will be UL and CE certified and scalable to 10,000 units per year. We will validate this device with consultation from established researchers at UCSD and device manufactures (Becton-Dickinson and Life Technologies).